Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
Botanix has announced that sublicensee Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products. The launch of ECCLOCK is expected to occur in the first quarter of 2026, and the product will be manufactured at Kaken’s Shizuoka plant in Japan.
The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.
Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.
#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
Click here to read the article.
Botanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.
Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
Euroz Hartleys has published a research note on Botanix maintaining a price target of $0.80.
The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™.
